Lipoprotein‐Mediated Esterified Oxylipins Changed in Alzheimer's Disease

Our data reveals significant alterations in lipoprotein-associated lipid mediators across the spectrum of cognitive decline from MCI to AD, with distinct changes observed in VLDL and LDL fractions. These findings indicate that lipoprotein-mediated oxylipin dysregulation is sex- and ApoE- specific, involving sEH and lipoxygenase/auto-oxidative pathways, highlighting the critical role of inflammation in AD pathology. This supports our hypothesis that lipoprotein composition influences neuroinflammatory processes and could complement the development of plasma biomarkers for AD.